Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the
treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum
Disorder. The main goal of this study is to begin to address the void of information on
safety, tolerability and effectiveness of Equetro in the treatment of Pediatric Bipolar
Disorder.